Bergen, 29 June 2006: NorDiag ASA today presents two clinical abstracts on the 8th World Congress on Gastrointestinal Cancer in Barcelona. The first abstract presents new data regarding the sensitivity of different combination panels of genetic markers for colorectal cancer detection. The second abstract demonstrates that routine use of genetic analysis is practically feasible and enables early clinical intervention, and confirms the high specificity of NorDiag`s first generation product.

- `The abstracts we are presenting in Barcelona show the international scientific and business community that genetic colorectal cancer testing can be performed effectively today, and that further product improvement through the inclusion of additional test markers may be a near term opportunity for us. With a basis in our proprietary methods and practical experience in this area, we feel confident that we are front runners in the field of applied DNA-based diagnostics of colorectal cancer and look forward to speak with the professionals
gathering in Barcelona`, says CEO Christian Horn in NorDiag.

The World Congress on Gastrointestinal Cancer is the largest congress of its kind, and attracts the top professionals and opinion leaders in the field.

The first abstract describes a blinded retrospective study performed on biopsy samples in collaboration with Norwegian gastroenterologists. NorDiag evaluated different combinations of genetic markers in order to determine the optimal combination for detection of colorectal cancer. These include markers not currently integrated in NorDiag`s product offer. Sensitivity values for the different marker panels studied reached up to approximately 84%
for cancer.

The second of the abstracts describes the use of NorDiag`s first generation Genefec assay to detect gene mutations associated with colorectal cancer in more than 3500 clinically selected samples. In about two thirds of the Genefec positive patients who were further examined by colonoscopy and had tissue material removed, the removal was done by polyp removal rather than comprehensive surgery. This demonstrates the advantage of earlier detection of colorectal cancer by Genefec. A further feature of this study was the very high specificity achieved (>99%) when analyzing stool specimens by non invasive stool DNA testing. The data is based on NorDiag`s first generation assay, which was based on detection of mutations in the K-ras gene. NorDiag`s current Genefec product also detects mutations in the p53 gene, such that this study only partially reflects the current product offer.

The two posters that NorDiag will present today can be found on our web pages under reports and presentations

Explanatory note: Sensitivity means the percentage of people with a disease correctly identified as such. Specificity means the proportion of people free of the disease correctly identified as such.

For further information, please contact:
CEO Christian Horn, NorDiag ASA, +47 90 16 31 53

About NorDiag:
NorDiag is a biotechnology company aiming to reduce mortality and treatment costs through detection of common cancers at the early, curable phases of cancer development. Early
cancer detection brings the dual benefits of better patient outcomes and reduced healthcare
costs. Currently NorDiag focuses on colorectal cancer through their product Genefec, a DNA
based test available and reimbursed as a clinical diagnostic test in Norway, Sweden and Denmark. NorDiag has substantial know how in the field of genetics and the extraction of human DNA from faeces. The Company`s operations are subject to patent protection, both through own applications and in-licensed rights to applicable patents. NorDiag has its offices in Bergen, Norway, and London, UK. For more information, please consul tthe Company`s web pages at www.nordiag.no